As of November 6, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Myriad Genetics Inc. The largest reported stake is BlackRock Portfolio Management LLC's, at 8.6%. 20 filings are on record since July 17, 2025 (Schedule 13G/A, October 27, 2026).
Sell to companies like Myriad Genetics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: BlackRock Portfolio Management LLC · Sole voting: 7,270,669 · Shared voting: 0 · Sole dispositive: 8,219,061 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-10-27
- · Holder: BlackRock Portfolio Management LLC · Percent: 10.4% · SCHEDULE 13G
- · Reporting person: Vestal Point Capital, LP · Sole voting: 0 · Shared voting: 5,735,000 · Sole dispositive: 0 · Shared dispositive: 5,735,000 · SCHEDULE 13G, 2026-08-14
- · Reporting person: Glenview Capital Management, LLC · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: State Street Corporation · Sole voting: 0 · Shared voting: 4,866,068 · Sole dispositive: 0 · Shared dispositive: 4,985,060 · SCHEDULE 13G, 2026-08-07
Myriad Genetics Inc has 20 Schedule 13D or 13G filings on record since 2025-07-17. 5 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| BlackRock Portfolio Management LLC | 8.6% | 8,219,061 | SCHEDULE 13G/A, 2026-10-27 | 2026-09-30 |
| BlackRock, Inc. | 8.5% | 7,976,163 | SCHEDULE 13G/A, 2026-04-07 | 2026-03-31 |
| Millennium Management LLC | 7.2% | 6,700,158 | SCHEDULE 13G/A, 2026-02-11 | 2025-12-31 |
| Vestal Point Capital, LP | 6.1% | 5,735,000 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| State Street Corporation | 5.3% | 4,985,060 | SCHEDULE 13G, 2026-08-07 | 2026-06-30 |
| Barclays PLC | 4.23% | 3,939,238 | SCHEDULE 13G/A, 2025-11-12 | 2025-09-30 |
| Disciplined Growth Investors Inc | 0.8% | 753,956 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-27 | 2026-03-13 |
| Wellington Management Group LLP | 0% | 0 | SCHEDULE 13G/A, 2025-08-12 | 2025-06-30 |
| Glenview Capital Management, LLC | 0% | 0 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
Holding shares or following this stake? See who's behind Myriad Genetics Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Myriad Genetics Inc and the records around it.
Myriad Genetics Inc elsewhere on the record
- Leadership changes Sep 2026
- Who owns it
Companies that share a holder
- GLENVIEW CAPITAL MANAGEMENT, LLC also filed stake reports on 6 other companies: Surgery Partners, Inc. (Oct 2026), Butterfly Network, Inc. (Aug 2026), DXC Technology Co (Aug 2026)
- DISCIPLINED GROWTH INVESTORS INC /MN also filed stake reports on 10 other companies: Alarm.com Holdings, Inc. (Aug 2026), Kornit Digital Ltd. (Aug 2026), Stitch Fix, Inc. (Aug 2026)
- Vestal Point Capital, LP also filed stake reports on 27 other companies: Alto Neuroscience, Inc. (Aug 2026), iBio, Inc. (Aug 2026), Immunocore Holdings plc (Aug 2026)
Watch Myriad Genetics Inc
Get an email when Myriad Genetics Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Myriad Genetics Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Myriad Genetics Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Myriad Genetics Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
23 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| BlackRock Portfolio Management LLC | 7,270,669 | 0 | 8,219,061 | 0 | SCHEDULE 13G/A, 2026-10-27 |
| Vestal Point Capital, LP | 0 | 5,735,000 | 0 | 5,735,000 | SCHEDULE 13G, 2026-08-14 |
| Ryan Wilder | 0 | 5,735,000 | 0 | 5,735,000 | SCHEDULE 13G, 2026-08-14 |
| State Street Corporation | 0 | 4,866,068 | 0 | 4,985,060 | SCHEDULE 13G, 2026-08-07 |
| Glenview Capital Management, LLC | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Robbins Larry | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Myriad Genetics Inc by CUSIP 62855J104 and gives its principal executive office as 322 NORTH 2200 WEST, SALT LAKE CITY, UT 84116 (SCHEDULE 13G/A, 2026-10-27).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-17 | BlackRock, Inc. | 15.3% | SCHEDULE 13G/A |
| 2025-07-29 | The Vanguard Group | 10.04% | SCHEDULE 13G/A |
| 2025-08-04 | Millennium Management LLC | 5.3% | SCHEDULE 13G/A |
| 2025-08-12 | Barclays PLC | 5.31% | SCHEDULE 13G |
| 2025-08-12 | Wellington Management Group LLP | 0% | SCHEDULE 13G/A |
| 2025-08-14 | Disciplined Growth Investors Inc | 0.8% | SCHEDULE 13G/A |
| 2025-10-31 | The Vanguard Group | 8.47% | SCHEDULE 13G/A |
| 2025-11-12 | Barclays PLC | 4.23% | SCHEDULE 13G/A |
| 2025-11-12 | Millennium Management LLC | 5.1% | SCHEDULE 13G/A |
| 2026-01-13 | Glenview Capital Management, LLC | 5.3% | SCHEDULE 13G |
| 2026-02-09 | State Street Corporation | 6.4% | SCHEDULE 13G |
| 2026-02-11 | Millennium Management LLC | 7.2% | SCHEDULE 13G/A |
| 2026-03-27 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-04-07 | BlackRock, Inc. | 8.5% | SCHEDULE 13G/A |
| 2026-05-12 | State Street Corporation | 4.7% | SCHEDULE 13G |
| 2026-08-07 | State Street Corporation | 5.3% | SCHEDULE 13G |
| 2026-08-14 | Vestal Point Capital, LP | 6.1% | SCHEDULE 13G |
| 2026-08-14 | Glenview Capital Management, LLC | 0% | SCHEDULE 13G/A |
| 2026-09-04 | BlackRock Portfolio Management LLC | 10.4% | SCHEDULE 13G |
| 2026-10-27 | BlackRock Portfolio Management LLC | 8.6% | SCHEDULE 13G/A |
Questions about who owns Myriad Genetics Inc
Who owns Myriad Genetics Inc?
On this page, 5 holders' latest ownership filings report 5% or more of Myriad Genetics Inc: BlackRock Portfolio Management LLC (8.6%, Schedule 13G/A, filed 2026-10-27), BlackRock, Inc. (8.5%, Schedule 13G/A, filed 2026-04-07), Millennium Management LLC (7.2%, Schedule 13G/A, filed 2026-02-11), Vestal Point Capital, LP (6.1%, Schedule 13G, filed 2026-08-14) and State Street Corporation (5.3%, Schedule 13G, filed 2026-08-07).
Who are the largest shareholders of Myriad Genetics Inc?
By the share each holder's latest filing reports, the largest holders of Myriad Genetics Inc on this page are BlackRock Portfolio Management LLC (8.6%), BlackRock, Inc. (8.5%) and Millennium Management LLC (7.2%).
When did BlackRock Portfolio Management LLC buy into Myriad Genetics Inc?
The filings give report dates, not purchase dates. The earliest filing from BlackRock Portfolio Management LLC on this page is the Schedule 13G, filed 2026-09-04, reporting 10.4%; its latest, Schedule 13G/A filed 2026-10-27, reports 8.6%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 20 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Myriad Genetics Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 9, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| September 16, 2026 | Leadership change: Vishal Sikri appointed, Senior Vice President, Product | — | Leadership changes | Source |
| June 23, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Myriad Genetics Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.